Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-01-04
2011-01-04
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S245000, C548S247000
Reexamination Certificate
active
07863308
ABSTRACT:
Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
REFERENCES:
patent: 2002/0013372 (2002-01-01), Ekins
patent: 2008/0033011 (2008-02-01), Tung
patent: 2008/0242687 (2008-10-01), Gant et al.
patent: 2008/0262006 (2008-10-01), Harbeson
patent: 2009/0005394 (2009-01-01), Harbeson
patent: 2009/0069351 (2009-03-01), Czarnik
patent: 2009/0069352 (2009-03-01), Czarnik
patent: 2009/0069353 (2009-03-01), Czarnik
patent: 2009/0069402 (2009-03-01), Czarnik
patent: 2010/0063076 (2010-03-01), Harbeson
patent: 2010/0093758 (2010-04-01), Sarshar et al.
patent: 9526325 (1995-10-01), None
patent: 9631492 (1996-10-01), None
patent: 00149685 (2001-07-01), None
patent: 2008088727 (2008-07-01), None
patent: 2008097468 (2008-08-01), None
patent: 2008122020 (2008-10-01), None
patent: 2008124803 (2008-10-01), None
patent: 2010011868 (2010-01-01), None
Wu, Chengde, et al, Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors, J. Med. Chem. 1999, 42, 4485-4499.
Bauer, LA. et al; Influence of long-term infusions on lidocaine kinetics; Clin. Pharmacol. Ther. 1982, 433-7.
Borgstrom, L. et al; Comparative Pharmacokinetics of Unlabeled and Deuterium-Labeled Terbutaline: Demonstration of a Small Isotope Effect; J Pharm Sci, 1988, 77(11), 952-4.
Browne, TR; Chapter 2. Isotope Effect: Implications for Pharmaceutical Investigations; Pharm Lib 1997 13.
Browne, TR et al.; Pharmacokinetic Equivalence of Stable-Isotope-Labeled and Unlabeled Drugs. Phenobarbital in Man; J Clin Pharmacol, 1982, 22, 309-315.
Burm, AGL et al; Pharmacokinetics of Lidocaine and bupivacaine and stable isotope-labeled analogs: a study in healthy volunteers; Biopharmaceutics and Drug Disposition, 1988, 9, 85-95.
Elison, C. et al; Effect of Deuteration of N-CH$—{3}$ Group on Potency and Enzymatic N-Demethylation of Morphine; Science, 1961, 134(3485), 1078-9.
Farmer, PB et al; Synthesis, Metabolism, and Antitumor Activity of Deuterated Analogues of 1-(2-Choloroethyl)-3-cyclohexyl-1-nitrosourea; Journal of Medicinal Chemistry, 1978, vol. 21, No. 6, 514-20.
Fisher, MB et al; The complexities inherent in attempts to decrease drug clearance by blocking sites of CYP-mediated metabolism; Curr Opin Drug Discov Develop; 2006, 9(1), 101-9.
Foster, AB; Deuterium Isotope Effects in Studies of Drug Metabolism; Trends in Pharmacological Sciences, Dec. 1984, 524-7.
Helfenbein, J. et al; Isotopic Effect Study of Propofol Deuteration on the Metabolism, Activity, and Toxicity of the Anesthetic; J. Med. Chem. 2002, 45, 5806-5808.
Kushner, DJ. et al; Pharmacological uses and perspectives of heavy water and deuterated compounds; Can J Phys Pharm 1999, 77, 79-88.
Lee, H. et al; Deuterium Magic Angle Spinning Studies of Substrates Bound to Cytochrome P450; Biochemistry 1999, 38, 10808-10813.
Mamada, K. et al; Pharmacokinetic Equivalence of Deuterium-Labeled and Unlabeled Phenytoin; Drug Metabolism and Disposition, 1986, 14(4), 509-11.
Nelson, SD et al; The Use of Deuterium Isotope Effect to Probe the Active Site Properties, Mechanism of Cytochrome P450-catalyzed Reactions, and Mechanisms of Metabolically Dependent Toxicity; Drug Metabolism and Disposition 31:1481-1498, 2003.
Nelson, SD et al; Primary and B-Secondary Deuterium Isotope Effects in N-Deethylation Reactions; Journal of Medicinal Chemistry, 1975, vol. 18, No. 11.
Pohl, L.R. et al; Determination of toxic Pathways of Metabolism by Deuterium Substitution; Drug—Metabolism—Rev—1985—1335.
Rampe, D. et al; Deuterated Analogs of verapamil and nifedipine. Synthesis and biological activity; Eur J Med Chem (1993) 28,259-263.
Wu, C;et al; Endothelin Antagonists: Substituted Mesitylcarboxamides with High Potency and Selectivity for ETa Receptors; J. Med. Chem., 1999, 42, 4485-99.
Lausecker, B. et al; Determination of an endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ionspray tandem mass spectrometry; Journal of Chromatography A, 1995, 712, 75-83.
Lausecker, B. et al; Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection; Journal of Chromatography B, 2000, 749, 67-83.
Lausecker, B. et al; Development of a liquid chromatographic/tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist; Journal of Mass Spectrometry, 2003, 38, 649-58.
Dell, D. et al; Evolving bioanalytical methods for the cardiovascular drug bosentan; Chromatographia, 2002, 55 (suppl), s-115-S-120.
Gant Thomas G.
Sarshar Sepehr
Auspex Pharmaceuticals, Inc.
Bennett Dennis A.
Saeed Kamal A
Sertic Michael
Shterengarts Samantha L
LandOfFree
Substituted thiophenes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted thiophenes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted thiophenes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2722190